Latest News

Rezolute (RZLT) just released topline data from its pivotal Phase 3 sunRIZE trial in congenital hyperinsulinism, and the drug missed both primary and key secondary endpoints, forcing investors to quickly reassess the story. See our latest analysis for Rezolute. The setback helps explain why Rezolute’s 30 day share price return sits at around negative 72 percent even after a sharp short term rebound. The share price closed at 2.74 dollars, and while the three year total shareholder return is...

Wondering whether Chemours at around $12 is a bargain or a value trap? You are not alone, and this breakdown is designed to help you decide with a clear, valuation-first lens. Despite a tough longer-term picture, with the stock still down 29.0% over the past year and 55.1% over three years, it has shown some short-term life, rising 3.4% in the last week and 4.3% over the past month, even though it remains down 28.2% year to date. Recent moves have been shaped by ongoing headlines around...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Zhou Liu Fu Jewellery fair value estimate is HK$34.07 Current...

Bosideng International Holdings Limited's ( HKG:3998 ) recent earnings report didn't offer any surprises, with the...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

When close to half the companies in Korea have price-to-earnings ratios (or "P/E's") above 14x, you may consider UIL...

Vault Minerals' (ASX:VAU) stock is up by a considerable 28% over the past three months. Given the company's impressive...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Wondering if Vita Coco Company at around $53 a share is still a refreshing opportunity or if most of the upside has already been squeezed out? You are not alone, and that is exactly what we are going to unpack here. The stock has climbed about 4.3% over the last week and 4.4% over the past month, while racking up a 52% gain year to date and 48.5% over the past year, with a 293.9% return over three years that has put it on growth investors radar. Behind these moves is a narrative around Vita...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

Artrya Limited recently announced a five-year SaaS agreement with U.S. healthcare provider Cone Health to roll out its Salix Coronary Anatomy and Plaque AI imaging modules across the health system’s network, securing its third commercial customer in the United States. This latest deal completes the conversion of all three of Artrya’s U.S. foundation partners, signalling growing clinical adoption and a deeper foothold in the competitive American cardiac imaging market. We’ll now examine how...

If you have been wondering whether Addus HomeCare is quietly turning into a value opportunity, you are not alone. Now may be a good time to take a closer look at the numbers. The stock has slipped about 1.7% over the last week and 4.2% over the past month, extending a 10.6% drop year to date and a 13.9% decline over the last year, even though it is still up 12.8% over three years. Recent headlines have focused on Addus expanding its footprint in personal care and home health through targeted...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

If you have been wondering whether Keurig Dr Pepper is quietly turning into a value opportunity or just a value trap, you are not alone. This is exactly what we are going to unpack. The stock has drifted lower over the longer term, with returns of about -11.1% over the last year and -11.8% year to date, even though it has managed a modest 2.3% gain over the last month. Recently, the company has stayed in the headlines for portfolio reshuffles, new beverage partnerships, and ongoing...

Frasers Centrepoint Trust (SGX:J69U) has posted FY 2025 second half results with revenue of about SGD 239 million and basic EPS of SGD 0.051, setting the stage for a year where trailing 12 month revenue sits around SGD 453 million and EPS at roughly SGD 0.10. The trust has seen revenue move from about SGD 200 million in 2H FY 2024 to SGD 239 million in 2H FY 2025 while trailing 12 month EPS has hovered just above SGD 0.10, leaving investors weighing modest earnings momentum against a squeeze...

If you are looking at Vail Resorts and wondering whether the recent share price weakness has finally turned this into a bargain, you are not alone. The stock is trading around $139.66 after a choppy spell, down 10.7% over the last week but still up 3.4% over the past month, while longer term returns, such as a 20.3% drop year to date and a 23.1% slide over the last year, keep many investors cautious. Recently, investors have been focused on how Vail is navigating changing travel patterns and...

As the Australian market approaches the holiday season, it's experiencing a slight dip, likely due to profit-taking and early closures, while Wall Street indices near record highs. In this environment of cautious optimism, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.

As the Australian market edges towards the holiday season with a slight dip, largely due to profit-taking and early closures, investors are keeping an eye on small-cap stocks amidst broader market fluctuations. In this environment, identifying promising yet overlooked companies can be key to enhancing your investment portfolio, especially as these gems may offer unique opportunities in times of economic shifts.

Topsports International recently reported that its total retail and wholesale sales for Q3 FY2025/26 fell by a high single‑digit percentage year-on-year, while the area of its directly operated stores contracted by 13.4% over the same period. This pullback in physical store space hints at a reshaping of Topsports International’s operating model, with potential consequences for revenue scale, customer experience, and relationships with brand partners. We’ll now explore how the ongoing...

ICL Group (NYSE:ICL) has quietly outperformed the broader market over the past week, with shares up about 10%, even as longer term returns remain mixed and commodity sentiment stays uneven. See our latest analysis for ICL Group. That recent 9.6% seven day share price return has only partly clawed back a weaker three month share price performance. However, with the stock now at $5.35 and a positive one year total shareholder return, momentum looks to be stabilising rather than breaking out. If...

In a robust market environment where the Dow Jones and S&P 500 have recently set new records, investors are keenly observing opportunities that may be overlooked amid widespread gains. Identifying undervalued stocks can be particularly rewarding in such conditions, as they offer potential value not yet recognized by the broader market.

Amidst a backdrop of record-setting highs for major indices like the S&P 500 and Dow Jones Industrial Average, the U.S. stock market continues to capture investor attention with its robust performance. In this thriving environment, discovering stocks that are not yet in the spotlight but show potential can be rewarding for investors seeking growth opportunities beyond blue-chip names.

Kanzhun Limited recently reshaped its leadership, with former Chief Financial Officer and executive Director Phil Yu Zhang becoming Chief Strategy Officer, Vice President Wenbei Wang stepping up as Deputy Chief Financial Officer, and Vice President of Human Resources Yang Mu joining the board as an executive Director, effective 11 December 2025. These appointments shift finance, strategy, and human resources voices at the top table, potentially influencing how Kanzhun balances growth...